双周剂量多西紫杉醇联合奥沙利铂及氟尿嘧啶治疗晚期胃癌临床观察(2)
 |
| 第1页 |
参见附件。
参 考 文 献
[1] Thuss2Patience PC,KretzschmarA,Reichardt P.Docetaxel in the treatment of gastric cancer.Future Oncol,2006,2(5):603-620.
[2] Eisenhauer EA,Vermorken JB.The taxoids.Comparative clinical pharmacology and therapeutic potential. Drugs,1998, 55(1):5-30.
[3] Sulkes A,Smyth J,Sessa C,et al.Docetaxel(Taxotere) in advancedgastric cancer:results of a phase Ⅱ clinical trial. EORTC Early Clini2cal Trial Group.Br J Cancer,1994,70(2):380-383.
[4] Taguchi T,Sakata Y,Kanamaru R,et al.Latephase Ⅱ clinical study ofRP56976 ( docetaxel) in patientswith advanced / recurrent gastric cancer: a Japanese Cooperative Study Group Trail(group A).Gan ToKagaku Ryoho,1998,25 (12):1915-1924.
[5] Ajani JA.Docetaxel for gastric and esophageal carcinomas. Oncolo2gy(Williston Park),2002,16(6 supp l6):89-96.
[6] Ajani JA,Moiseyenko VM, Tjulandin,et al.Quality of life with docetaxel plus cisp latin and fluorouracil compared with cisp latin and fluorouracil from a phase Ⅲ trial for advanced gastricor gastroesophageal adenocarcinoma:the V2325 Study Group.J Clin Oncol,2007,25(22):3210-3216.
[7] Ajani JA,Moiseyenko VM,Tjulandin S,et al.Clinical benefit with docetaxel plus fluorouracil and cisp latin compared with cisp latin and flu2orouracil in a phase Ⅲ trial of advanced gastic or gastroesophageal ade2nocarcinoma:the V2325 Study Group.J Clin Oncol,2007,25(22):3205-3209.
(收稿日期：2011-07-25)
(本文编辑:陈丹云)
您现在查看是摘要介绍页，详见PDF附件。